[go: up one dir, main page]

DK0500847T3 - Behandling af obesitas med en alfa-2-adrenergisk agonist og et væksthormonfrigørende peptid - Google Patents

Behandling af obesitas med en alfa-2-adrenergisk agonist og et væksthormonfrigørende peptid

Info

Publication number
DK0500847T3
DK0500847T3 DK91914999.7T DK91914999T DK0500847T3 DK 0500847 T3 DK0500847 T3 DK 0500847T3 DK 91914999 T DK91914999 T DK 91914999T DK 0500847 T3 DK0500847 T3 DK 0500847T3
Authority
DK
Denmark
Prior art keywords
growth hormone
alpha
adrenergic agonist
obesity
treatment
Prior art date
Application number
DK91914999.7T
Other languages
Danish (da)
English (en)
Inventor
Jesus Devesa Mugica
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of DK0500847T3 publication Critical patent/DK0500847T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK91914999.7T 1990-09-10 1991-09-06 Behandling af obesitas med en alfa-2-adrenergisk agonist og et væksthormonfrigørende peptid DK0500847T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/580,686 US5120713A (en) 1990-09-10 1990-09-10 Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide

Publications (1)

Publication Number Publication Date
DK0500847T3 true DK0500847T3 (da) 1996-01-08

Family

ID=24322121

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91914999.7T DK0500847T3 (da) 1990-09-10 1991-09-06 Behandling af obesitas med en alfa-2-adrenergisk agonist og et væksthormonfrigørende peptid

Country Status (11)

Country Link
US (1) US5120713A (fr)
EP (1) EP0500847B1 (fr)
JP (1) JP3255289B2 (fr)
AT (1) ATE131063T1 (fr)
AU (1) AU650048B2 (fr)
CA (1) CA2072624C (fr)
DE (1) DE69115247T2 (fr)
DK (1) DK0500847T3 (fr)
ES (1) ES2080331T3 (fr)
GR (1) GR3018922T3 (fr)
WO (1) WO1992004040A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428013A (en) * 1991-01-04 1995-06-27 Mugica; Jesus D. Differential diagnosis and treatment of the states of growth hormone insufficiency (or deficiency) with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US6129685A (en) * 1994-02-09 2000-10-10 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US7077822B1 (en) 1994-02-09 2006-07-18 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US5605886A (en) * 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US6231594B1 (en) 1999-08-11 2001-05-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CA2434488A1 (fr) * 2001-01-26 2002-08-01 Harry R. Davis Combinaisons d'acide nicotinique et de derives de ce dernier, inhibiteur(s) d'absorption de sterols et traitements de conditions vasculaires
ATE362757T1 (de) * 2001-01-26 2007-06-15 Schering Corp Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
AU2002241956A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002243557B2 (en) * 2001-01-26 2006-01-05 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
AR032403A1 (es) * 2001-01-26 2003-11-05 Schering Corp Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
PL208110B1 (pl) * 2001-01-26 2011-03-31 Schering Corp Kompozycja farmaceutyczna
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US6582457B2 (en) * 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
DE60216275T2 (de) * 2001-05-25 2007-06-21 Schering Corp. Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
JP2005504043A (ja) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
PT1427409E (pt) * 2001-09-21 2008-11-27 Schering Corp Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA05004810A (es) * 2002-11-06 2005-07-22 Schering Corp Inhibidores de la absorcion del colesterol para el tratamiento de la desmielinizacion.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
EP1606287B1 (fr) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Composés d'azetidinone substitués, formulations et utilisations de ceux-ci pour traiter l'hypercholestérolémie
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
EP1680189A2 (fr) * 2003-11-05 2006-07-19 Schering Corporation Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2009043520A1 (fr) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
IT1191611B (it) * 1985-05-15 1988-03-23 Eugenio E Muller Formalazioni farmaceutiche per stimolare la liberazione di ormone somatotropo
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative

Also Published As

Publication number Publication date
JPH05503710A (ja) 1993-06-17
EP0500847A1 (fr) 1992-09-02
DE69115247D1 (de) 1996-01-18
GR3018922T3 (en) 1996-05-31
CA2072624A1 (fr) 1992-03-11
CA2072624C (fr) 1999-03-23
WO1992004040A1 (fr) 1992-03-19
JP3255289B2 (ja) 2002-02-12
AU8430591A (en) 1992-03-30
US5120713A (en) 1992-06-09
ATE131063T1 (de) 1995-12-15
EP0500847B1 (fr) 1995-12-06
ES2080331T3 (es) 1996-02-01
AU650048B2 (en) 1994-06-09
DE69115247T2 (de) 1996-07-25

Similar Documents

Publication Publication Date Title
DK0500847T3 (da) Behandling af obesitas med en alfa-2-adrenergisk agonist og et væksthormonfrigørende peptid
DK0415613T3 (da) Anvendelse af sertralin til behandling af præmatur ejakulation
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
DK1316308T3 (da) Transdermalt terapeutisk plaster med capsaicin og capsaicin-analoger
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
DK0611572T3 (da) Fremgangsmåde til fremstilling af et frysetørret cetrorelix præparat
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
ATE100714T1 (de) Arzneimittel (calcitoningen verwandte peptide) zur behandlung erektiler dysfunktionen.
ATE183397T1 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
DK0591130T3 (da) Ortopædisk stöttebandagesystem og komponenter dertil
ATE144149T1 (de) Therapeutisches verfahren zur behandlung von iddm
DK0901790T3 (da) Anvendelse af moxonidin til behandling af neuropatisk smerte
ES2025107B3 (es) Vendaje para el tratamiento de dolencias en el antebrazo
IL101675A (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
AU8230187A (en) N,n'-bis-amino acid-l-cystine-peptide-containing amino acid preparations for oral and parenteral administration
GR3007210T3 (fr)
ES2085199B1 (es) Un procedimiento para la preparacion de una formulacion depot.
DK272789D0 (da) Fremgangsmaade og praeparat til behandling af infertilitet
ES2158857T3 (es) Vacunas a base de estreptoquinasa.
CY1108368T1 (el) Διαδερμικη συσκευη φελοδιπινης και μεθοδοι
DE69131629D1 (de) Behandlung fehlender milchabsonderung beim menschen
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
DK0484429T3 (da) Fremgangsmåde til behandling af infertilitet eller sub-fertilitet hos voksne mænd, og brugen af præparater til fremgangsmåden
BG49742A1 (en) Affrodisiance means
RU2001124669A (ru) Способ профилактики паратифа телят